Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial-Reference-Cited by-同舟云学术

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Published:2017-03 Issue:3 Volume:76 Page:418-431
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Reich Kristian,Armstrong April W.,Foley Peter,Song Michael,Wasfi Yasmine,Randazzo Bruce,Li Shu,Shen Y.-K.,Gordon Kenneth B.

Publisher

Elsevier BV

Subject

Dermatology

Reference31 articles.

1. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey;Lebwohl;Am J Clin Dermatol,2016

2. Unmet needs in the treatment of psoriasis;Kragballe;Eur J Dermatol,2014

3. Patient-relevant treatment goals in psoriasis;Blome;Arch Dermatol Res,2016

4. Clinical meaningfulness of complete skin clearance in psoriasis;Strober;J Am Acad Dermatol,2016

5. Review of maintenance of response to psoriasis treatments;Bartos;J Dermatolog Treat,2016

Cited by 591 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study;Clinical Pharmacology in Drug Development;2024-09-04

2. Newer Therapies in Rheumatology;Medical Clinics of North America;2024-09

3. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

4. Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab;JAAD International;2024-09

5. Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy;JID Innovations;2024-09